MRI Contrast Agents Go Head-to-Head: Researchers Find Greater Morphologic Information and Lesion Enhancement with Bracco Diagnostics Inc.’s MultiHance® (gadobenate dimeglumine) Injection, 529 mg/mL When Compared to Gadavist™ (gadobutrol injection)

Published: Mar 07, 2012

PRINCETON, N.J.--(BUSINESS WIRE)--A new study shows that the use of gadobenate dimeglumine, the highest relaxivity gadolinium-based contrast agent (GBCA) available for central nervous system (CNS) magnetic resonance imaging (MRI), over a high concentration MRI contrast agent may improve clinicians’ ability to visualize lesions of the brain.

Back to news